2006 OCF Grant

A double-blind, placebo-controlled trial of N-acetylcysteine in SRI-resistant OCD

Vladimir Coric, MD

Yale University School of Medicine/Connecticut Mental Health Center (New Haven, CT)

Award Amount: $36,600.

Although the initial focus of this study by Dr. Coric and his team was how N-acetylcysteine would supplement the effectiveness of serotonin reuptake inhibitors for treating OCD, this research resulted in an exploration of how medications that target glutamate (one of the most important neurotransmitters linked to learning, memory, and mood) could be used to reduce OCD symptoms. The study confirmed the role of glutamate in OCD and reviewed multiple treatment strategies involving glutamate modulation, concluding that glutamate modulation via certain medications is a promising means of treating OCD.


Resulting Publication:

*Pittenger, C., Krystal, J.H., & Coric, V. (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx, 3, 69-81